glp 1 gip dual agonist lilly GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 Move over #retatrutide the #QuintupleAgonist

Based on this review, evidence from head-to-head and insulin-comparator trials demonstrates that dual GIP/GLP-1 co-agonism consistently overcomes metabolic plateaus that result from single-pathway therapy, producing superior glycated hemoglobin reduction, bariatric-level weight loss (up to 25.3%), and robust macrovascular and heart failure protection, including a 38% reduction in composite cardiovascular risk among patients with heart failure with preserved ejection fraction (HFpEF)

GLP-1 research tablet provides 25 x 7mg tablets of GLP-1 receptor agonist studied in preclinical models for incretin-pathway signaling, metabolic regulation, and energy-balance pathways

This wildly popular drug is a synthetic form of GLP-1 (glucagon-like peptide-1), a hormone that regulates blood sugar and curbs appetite

Learn how to increase GLP-1 naturally using evidence-based nutrition

Now Pfizers public declaration that its at the end of the beginning in entering the GLP1 market marks a pivotal

Are GLP-1 drugs an 'existential threat' to the food industry or an opportunity to cash in with 'companion' products and 'Nature's Ozempic'?